Physician profile
Luke Hall
NPI 1740800150
$2,474.95
in general payments reported to CMS, 2019-2025
26 companies · $804 in 2025
The $804 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $533 · 2024: $1,138 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.10 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $563.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $341.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $299.83 | 2023-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $270.59 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $147.74 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Heartflow, INC. | $131.94 | 2024 | |
| Pfizer INC. | $106.45 | 2024-2025 | |
| Astellas Pharma US INC | $89.32 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $75.00 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $57.92 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $50.68 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $40.17 | 2024-2025 | |
| Lundbeck LLC | $39.12 | 2024-2025 | Vyepti |
| Inspire Medical Systems, INC. | $37.38 | 2023 | Inspire |
| Seqirus USA INC | $35.01 | 2024 | Fluad, Flucelvax |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.87 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $18.86 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2025 | |
| Daiichi Sankyo INC. | $18.23 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $15.21 | 2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Baxter Healthcare | $14.99 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $14.58 | 2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.20 | 2024 | Caplyta |
| Tris Pharma INC | $14.17 | 2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $13.72 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.